Article

CyanoCapture and Persist AI announced a collaboration to build a GMP manufacturing facility in the San Francisco Bay Area, operational by Q4 2026. This facility will integrate cyanobacteria-based drug delivery with AI-driven robotics for the production of oral protein and peptide therapeutics, addressing the challenge of delivering biologics orally instead of via injection. The partnership aims to enhance drug development speed and precision using AI in the manufacturing process.